Aminorex

Aminorex
Clinical data
Other names	Aminoxaphen; Aminoxafen; McN-742
ATC code	none;
Legal status
Legal status	BR: Class B2 (Anorectic drugs); CA: Schedule III; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class C; US: Schedule I;
Identifiers
	IUPAC name (RS)-5-Phenyl-4,5-dihydro-1,3-oxazol-2-amine;
CAS Number	2207-50-3 ;
PubChem CID	16630;
DrugBank	DB01490 ;
ChemSpider	15767 ;
UNII	2SH16612I9;
KEGG	D02909 ;
ChEMBL	ChEMBL106258 ;
CompTox Dashboard (EPA)	DTXSID00862867 ;
ECHA InfoCard	100.164.420
Chemical and physical data
Formula	C9H10N2O
Molar mass	162.192 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES NC1=NCC(C2=CC=CC=C2)O1;
	InChI InChI=1S/C9H10N2O/c10-9-11-6-8(12-9)7-4-2-1-3-5-7/h1-5,8H,6H2,(H2,10,11) ; Key:SYAKTDIEAPMBAL-UHFFFAOYSA-N ;
	(verify)

Aminorex, sold under the brand names Menocil and Apiquel among others, is a weight loss (anorectic) stimulant drug. It was withdrawn from the market after it was found to cause pulmonary hypertension (PPH). In the United States, aminorex is a Schedule I controlled substance.

Aminorex, in the 2-amino-5-aryloxazoline group, was developed by McNeil Laboratories in 1962. It is closely related to 4-methylaminorex (4-MAR). Aminorex has been shown to have locomotor-stimulant effects, lying midway between dextroamphetamine and methamphetamine. Aminorex effects have been attributed to the release of catecholamines. It can be produced as a metabolite of the deworming medication levamisole, which is sometimes used as a cutting agent of illicitly produced cocaine.